What's hot

View all perspectives
What's Hot

JAK Safety -- The Lowdown on Infection: Drs. Kevin Winthrop and Jonathan Kay

Watch video →

RheumNow Rheumatology Roundup: Drs. Kavanaugh and Cush

Rheumatology Roundup! Drs. Cush and Kavanaugh convene for their annual impromptu review of some of the best and more interesting abstracts presented at ACR 2021.    

Watch video →

TNF Inhibitor Panel Discussion: ACR21 Annual Meeting

RheumNow TNFi faculty convened to discuss several TNFi-related abstracts presented at ACR 21. Panelists: Drs. Aurelie Najm, Janet Pope, David Liew, Eric Dein and Swetha Alexander. 

Watch video →

Spondyloarthritis Panel Discussion: ACR21 Meeting

Panelists: Drs. Antoni Chan, Robert Chao, Rachel Tate, Sheila Reyes and Akhil Sood. Abstracts discussed include #0562, #1919, #0907, #0364 and #0919

Watch video →

Might Tofacitinib Reduce Malignancy Risk with Patients with RA? Dr. Jonathan Kay

Dr. Kay discusses abstract 1940 and abstract 980 presented at the ACR21 annual meeting.

Watch video →

Diagnosing (Bad) VEXAS: The Experts Speak Drs. Beck and Ferrada

Dr. Cush discusses Dr. Marcela Ferrada and Dr. David Beck to discuss VEXAS syndrome and abstract 1426, which was presented at the ACR21 annual meeting.

Watch video →

Pediatric Psoriatic Arthritis: Dr. Eric Ruderman

Dr. Ruderman discusses abstracts #1424 presented at the ACR21 annual meeting.

Watch video →

Urine Proteome Advances: What Do They Mean? Dr. Michelle Petri

Dr. Petri reviews abstracts #1422 and #1936, presented at the ACR21 annual meeting.

Watch video →

ACR21 Day 3 Recap: Polypharmacy, New Lupus Drugs, VEXAS, Safety Data

Blurb: Drs. Jack Cush and the RheumNow Faculty Drs. Akhil Sood, Antoni Chan, Olga Petryna and Eric Dein, discuss highlights from Day 3 (Monday) at the ACR21 annual meeting. Abstracts include #1367, #1044, #1444, #1083 and more.

Watch video →

Cardiovascular Disease for TNFi vs JAKi: Dr Jon Giles

Dr. Giles discusses abstracts #0831and #0958 presented at the ACR21 annual meeting.

Watch video →

Predictors of TNF Response with Drs. Pope, Dein and Liew

Drs. Janet Pope, David Liew and Eric Dein discuss TNF data presented at the ACR21 annual meeting, including abstracts #1251, #1442, #1448.

Watch video →

Caring for the Older Patient with Rheumatic Disease: Drs. Makris, Yung and Dao

Drs. Kathryn Dao, Una Makris and Raymond Yung discuss the field of geriatric rheumatology and caring for the older patient with rheumatic disease.

Watch video →

Autoinflammatory: PAH in AOSD, VEXAS, JAKi in Still's, Role of labs in infections vs. flares

  Drs. Jack Cush, Yuz Yusof, Bella Mehta, Olga Petryna and Rachel Tate review autoinflammatory data presented at the ACR21 annual meeting, including abstracts #1100, #1062, #1426, #0252, #0195, and #1083.

Watch video →

FDA Session Review: Dr. Arthur Kavanaugh

Dr. Kavanaugh discussed the FDA session presented at the ACR21 annual meeting, including safety data and new approvals and indications in several rheumatic diseases, including lupus, ANCA-associated vasculitis, lupus nephritis and more.

Watch video →

The Respiratory Tract and RA with Drs. Sparks, McDermott and Kronzer

Drs. Jeffrey Sparks, Greg McDermott and Vanessa Kronzer discuss work in the area of respiratory disease in RA, mucosal paradigm, RA-ILD, bronchiectasis, as well as their experience as virtual attendees at the ACR21 annual meeting.

Watch video →

Pulmonary Hypertension in Adult Onset Still's Disease: Dr. Jack Cush

Dr. Cush reviews poster #1100 presented at the ACR21 annual meeting.

Watch video →

Data on Existing SLE Medications, Patient Centered Outcomes, and Exercise: Dr. Michelle Petri

Dr. Petri discusses data on existing SLE medications, patient-centered outcomes and the importance of exercise, presented Monday at the ACR21 annual meeting.

Watch video →

ACR21 Day 2 Recap: CV Risk, Tapering in SpA, Microbiome in PsA, Vit D

Drs. Jack Cush and the RheumNow Faculty Drs. David Liew, Swetha Ann Alexander, Meral El Ramahi, Mrinalini Dey and Robert Chao, discuss highlights from Day 2 (Sunday) at the ACR21 Virtual meeting.

Watch video →
      RT @DrPetryna: Abst 0452 #ACR21 #acrbest @RheumNow TB-PET/CT in PsA helps differentiate from RA/OA &measure inflamma

      Olga Petryna DrPetryna

      4 years ago
      Abst 0452 #ACR21 #acrbest @RheumNow TB-PET/CT in PsA helps differentiate from RA/OA &measure inflammatory burden. Main findings asymmetric synovitis,systemic enthesitis, DIP& extensor tendons inflammation& adjacent nail matrix inflammation, Sacroiliitis& diffuse spine enthesitis https://t.co/7nTSIbmKfE
      RT @uptoTate: ASRI data: high frequency of pregnancy and fetal complications (miscarriage, c-section, early delivery, NI

      Dr. Rachel Tate uptoTate

      4 years ago
      ASRI data: high frequency of pregnancy and fetal complications (miscarriage, c-section, early delivery, NICU admission) in AxSpA pts. We need more studies regarding risks/tx/outcomes/breastfeeding guidance. Abs 0369 #ACR21 #RheumNow @RheumNow https://t.co/4BR2ZPPjyB https://t.co/qyTwtfEMMy
      RT @Janetbirdope: #ClinicalPearl Leflunomide for chronic CMV retinitis failing antiviral Rx? Suppresses inflammation &am

      Janet Pope Janetbirdope

      4 years ago
      #ClinicalPearl Leflunomide for chronic CMV retinitis failing antiviral Rx? Suppresses inflammation & Arava May have antiviral properties. Didn’t know it. Kolfenbach & Palestine 6S117 eye opening experiences #ACR21 @RheumNow
      RT @DrMiniDey: What increases risk of RA-assoc #bronchiectasis, separate from #RA-ILD?

      Results from @BrighamResearch fi

      Mrinalini Dey DrMiniDey

      4 years ago
      What increases risk of RA-assoc #bronchiectasis, separate from #RA-ILD? Results from @BrighamResearch find seropositivity (esp high +ve RF/CCP), older age, disease duration, & low BMI incr. risk of isolated bronchiectasis in RA. #ACR21 Abs#0288 @RheumNow https://t.co/jvvRucqTjL https://t.co/aFCfxrbUdV
      RT @_Castillo_Pedro: Dr. Petri et al showed transition between lupus anticoagulant (-) to (+), (+) to (-), and (+) or (-

      Pedro Castillo _Castillo_Pedro

      4 years ago
      Dr. Petri et al showed transition between lupus anticoagulant (-) to (+), (+) to (-), and (+) or (-) to thrombosis could be estimated by multistate Markov model. #ACR21 Abst#0076 @RheumNow https://t.co/oIvbak4lV4
      RT @KDAO2011: Retrospective study of FAERS database: 186 irAE w/rheum manifestation
      👉4.7% of all AEs
      👉Arthritis, m

      TheDaoIndex KDAO2011

      4 years ago
      Retrospective study of FAERS database: 186 irAE w/rheum manifestation 👉4.7% of all AEs 👉Arthritis, myositis, Sjogren, sarcoidosis were frequent 👉myositis assc w/ durvalumab, avelumab, atezolimumab and cemiplimab #ACR21 Abstr#0438 #Plenary @rheumnow https://t.co/t8UQWQicFc https://t.co/FGo6WCDQTp
      RT @RHEUMarampa: @BethIWallace et al. on fibromyalgianess and GC in #rheumatoidarthritis pts.
      Accdg to their study, pt

      sheila RHEUMarampa

      4 years ago
      @BethIWallace et al. on fibromyalgianess and GC in #rheumatoidarthritis pts. Accdg to their study, pts w/⬆ levels of fibromyalgianess at BL had higher odds of GC persistence on ffup. Something to consider when evaluating need for GC adjustment. @RheumNow #ACR21 abs0120 https://t.co/MTWEXGHJ2n
      RT @KDAO2011: Retrospective study of cancer pts Rx w/ ICI and autoimmune Ab (ANA, RF, CCP, SSA/SSB, ANCA)
      👉152 pts
      ð

      TheDaoIndex KDAO2011

      4 years ago
      Retrospective study of cancer pts Rx w/ ICI and autoimmune Ab (ANA, RF, CCP, SSA/SSB, ANCA) 👉152 pts 👉59% had irAE 👉preICI Ab+⬆️odds of irAE (OR 17.5 95% CI 1.76-174, p=0.015) 👉strong assc b/t +RF and +CCP for ICD-arthritis #ACR21 Abst#0440 @Rheumnow https://t.co/kUv5ddSAnY
      RT @jeffsparks: Large case-control study (n=8028) to identify baseline predictors of rheum irAEs after immune checkpoint

      Jeffrey Sparks MD MMSc jeffsparks

      4 years ago
      Large case-control study (n=8028) to identify baseline predictors of rheum irAEs after immune checkpoint inhibitor initiation for cancer. Type of cancer (melanoma, GU), combination ICI, pre-existing autoimmune disease, and recent GC use each had higher odds of rheum irAE #ACR21 https://t.co/rHI6VQ37QB
      RT @Janetbirdope: #ClinicalPearl Joint clinic btwn ophthalmology & #rheumatology helps make dx & Rx work. #ACRBe

      Janet Pope Janetbirdope

      4 years ago
      #ClinicalPearl Joint clinic btwn ophthalmology & #rheumatology helps make dx & Rx work. #ACRBest #ACR21 see work up of inflammatory eyes disease. All are allowed one acute ant uveitis- ? dogma maybe work up all. 6S117 https://t.co/Wwdv3N66HS
      RT @MeralElRamahiMD: #ACR21 Abst#0290:
      Ever wonder about other predictors of mortality in pts w/ RA-Lung Disease beside

      Meral K. El Ramahi, MD MeralElRamahiMD

      4 years ago
      #ACR21 Abst#0290: Ever wonder about other predictors of mortality in pts w/ RA-Lung Disease besides ILD (OR 2.3) or older age? ⭐︎ ↑ mortality associated w/ pleural effusions (OR 3.3) AND, notably... ⭐︎MTX use was protective (OR 0.4)!!! @RheumNow https://t.co/KKRkQVY2pf https://t.co/JsU2Rqzi6R
      RT @RHEUMarampa: This study looked into the prevalence of subclinical atherosclerosis in #rheumatoidarthritis pts w/n 5

      sheila RHEUMarampa

      4 years ago
      This study looked into the prevalence of subclinical atherosclerosis in #rheumatoidarthritis pts w/n 5 yrs of dx using carotid US. 📌vs. controls, RA pts had ⬆ CPs, cIMT ❗Screen RA pts for CV risk early on in their diagnosis @RheumNow #ACR21 abs0271 https://t.co/btU6IcM3xb
      RT @uptoTate: ASAS-PerSpA worldwide study: axSpA most common SpA from in family hx. Except in Middle Eastern/N. African

      Dr. Rachel Tate uptoTate

      4 years ago
      ASAS-PerSpA worldwide study: axSpA most common SpA from in family hx. Except in Middle Eastern/N. African pts, a FH of axSpA associated w/ +HLA-B27 in axSpA pts. PsO and IBD FH more likely -HLA-B27 . FH of ReA rare. Abs 0368 #ACR21 #RheumNow @RheumNow https://t.co/iHBccAcvLi https://t.co/FCoyVg3MGw
      RT @ericdeinmd: #ACR21 Abst#0293
      RA patients with lung disease have increased rates of SSc-specific autoantibodies compa

      Eric Dein ericdeinmd

      4 years ago
      #ACR21 Abst#0293 RA patients with lung disease have increased rates of SSc-specific autoantibodies compared to RA w/o lung disease. ▶️ Suggests we may need to investigate further into overlap phenotype in RA-ILD @Rheumnow https://t.co/04FFuBUKmA https://t.co/A83kaie2gr
      RT @Janetbirdope: #ClinicalPearl. ‘my eye hurts-what’s going on!’ Dr Palestine says Ophthalmologists don’t agree

      Janet Pope Janetbirdope

      4 years ago
      #ClinicalPearl. ‘my eye hurts-what’s going on!’ Dr Palestine says Ophthalmologists don’t agree on uveitis naming/ethology & worse - Rheums & eye specialists don’t speak language. Need to know infections are r/o (syphillis, CXR) & if active uveitis to ⬆️Rx #ACR21 @RheumNow https://t.co/7LkhJnUKXK

      Podcasts

      • Giant Cell Arteritis and Polymyalgia Rheumatic Wrapup: Drs. Calabrese, Liew, Conway and Mackie 00:20:18
      • Reproductive Health in Rheumatic Diseases: Drs. Bermas, Buyon and Dao 00:20:26
      • The Expert Gout Panel with Drs. Neogi, Saag, Pillinger, Cush and O'Dell 00:35:26

      Catch up on Conference Podcasts

      ×